Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Share-based Compensation (2021 - 2023)

Cullinan Therapeutics has reported Share-based Compensation over the past 3 years, most recently at $7.5 million for Q4 2023.

  • Quarterly results put Share-based Compensation at $7.5 million for Q4 2023, changed 0.08% from a year ago — trailing twelve months through Dec 2023 was $30.4 million (up 8.87% YoY), and the annual figure for FY2025 was $36.0 million, down 4.72%.
  • Share-based Compensation for Q4 2023 was $7.5 million at Cullinan Therapeutics, down from $7.7 million in the prior quarter.
  • Over the last five years, Share-based Compensation for CGEM hit a ceiling of $12.1 million in Q4 2021 and a floor of $3.5 million in Q1 2021.
  • Median Share-based Compensation over the past 3 years was $7.4 million (2022), compared with a mean of $6.9 million.
  • Peak annual rise in Share-based Compensation hit 106.67% in 2022, while the deepest fall reached 38.14% in 2022.
  • Cullinan Therapeutics' Share-based Compensation stood at $12.1 million in 2021, then crashed by 38.14% to $7.5 million in 2022, then increased by 0.08% to $7.5 million in 2023.
  • The last three reported values for Share-based Compensation were $7.5 million (Q4 2023), $7.7 million (Q3 2023), and $7.9 million (Q2 2023) per Business Quant data.